OTHER TOOLS AND RESOURCES
|Human, mouse, rat, chicken, yeast, cow horse
DESCRIPTION: Anti-Diglycyl-lysine antibody, clone GX41
SPECIFICITY: Antibody recognizes lysine residues modified by diglycine, an adduct left at sites of ubiquitination after trypsin digest.
SOURCE/PURIFICATION: Monoclonal antibodies are produced by immunizing animals with a synthetic diglycine-modified histone peptide and established in hybridoma line GX41. Antibodies are purified by protein A and peptide affinity chromatography.
PRESENTATION: Lysophilized IgG
STORAGE CONDITIONS: Stable for 2 year at -20 ºC.
QUALITY ASSURANCE: Each antibody batch is measured for its ability to bind to proteins containing diglycyl-lysine and to recover diglycyl-lysine-containing peptides from tryptic digests of HEK293 cells.
USAGE STATEMENT: This product is intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. Due to the highly specific nature of antibodies and antigens, we cannot predict or be held responsible with respect to how LucernaTM products will behave in its customers' systems. Researchers using LucernaTM products should conduct optimization studies to achieve the optimal result possible for their intended application.
LICENSING: Cornell University has filed a use patent on proteomic methods that use the diglycyl-lysine antibody to identify ubiquitinated proteins. All commercial users should contact Cornell University for a use license.
GX41 antibody recognizes the diglycyl-lysine moiety at ubiquitinated sites after trypsin digestion
Specificity of anti-diglycyl-lysine (clone GX41) is verified by western blot analysis of beta-lactoglobulin, lysozyme, or rat brain lysate, in which the lysines were either unmodified (A) or modified with Gly-Gly (B), respectively. As shown above, the GX41 exhibits no detectable reactivity with proteins unless the lysines are modified with Gly-Gly.
Equimolar amounts of the two peptides (GGDRVYIHPFHL and Ac-SYSMEHFRWGK*PV-NH2) were immunoprecipitated with immobilized GX41 antibody and analyzed by MALDI-TOF MS. K* refers to a lysine with a Gly-Gly modification. As shown above, the unmodified peptide is absent from the immunoprecipitate, while the peptide containing the Gly-Gly modification is immunoprecipitated.
REFERENCE FOR THE PRODUCT:
Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling. Xu G, Paige JS, Jaffrey SR.Nature Biotechnology. 2010 Aug;28(8)868-73.
THIS PRODUCT WAS CITED IN:
A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread of regulatory roles. Wagner SA, et al. Molecular & Cellular Proteomics. 2011 Sep
Proteomic analyses reveal divergent ubiquitylation site patterns in murine tissues. Wagner SA, et al. Molecular & Cellular Proteomics. 2012 Jul.
Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Povlsen LK, et al. Nature Cell Biology. 2012 Sep.